Key Takeaways
- Record sales, compressed margins: Group delivered its highest ever quarterly sales, but EBITDA margin fell to 6.4% as the company chose volume leadership over price in a buyer's market.
- Mahad is the margin swing factor: The greenfield plant is EBITDA negative and dragging Group margins by 1.5–2 percentage points; its ramp-up over the next few quarters is the single largest lever for the promised recovery to an 8–10% target range.
- Chinese oversupply is the external threat: Chinese producers, locked out of the US by tariffs, are aggressively selling into India, Southeast Asia and the EU, keeping a lid on pricing across the entire aroma ingredients portfolio.
- Camphor faces a domestic capacity glut: Multiple Indian players have built substantial synthetic camphor capacity into a market that has not expanded, creating a structural oversupply that management calls the bigger challenge to profitability.
- What to watch next quarter: Whether Mahad reaches EBITDA breakeven, any sign that Chinese competitive intensity is easing, and the pace of benefits from the internal cost-reduction program.
The Conscious Margin Trade-Off
- Volume over price: Management explicitly chose to align selling prices with the market to protect market share and customer relationships, accepting a margin decline from 8% to 6.4% as the cost of that decision.
- Blended price decline: Selling prices fell ~6% on a blended basis, with some products seeing substantial reductions and others less; the pressure spans all existing products including camphor.
- Cost mitigation in progress: An internal CPR (cost reduction) program is targeting process improvements and batch-time cycle reductions; benefits are expected in coming quarters and should enable better margins even at current price levels.
- Input cost headwinds: Pinene prices remain firmed up and rupee depreciation adds temporary cost pressure, compounding the selling-price squeeze.
Parag Satoskar: "It was a conscious decision to hold for, ensure that our market share in every business that we currently have stays."
Mahad: The Ramp-Up Drag
- Current state: The Mahad greenfield plant is EBITDA negative and pulling down consolidated margins by 1.5 to 2 percentage points. Per-kg profitability is positive, but sales volumes have not yet ramped enough to cover fixed costs.
- Why volumes lag: A full cycle of sampling approvals and commercial shipments takes five to six months; the plant missed the H2 2025 RFQ season and is now seeing rapid adoption begin. Capacity utilization sits around 20–21% on an annual capacity of 250 metric tonnes.
- The breakeven question: Management did not have the minimum capacity utilization needed for EBITDA breakeven at current pricing and committed to follow up.
- Recovery timeline: The plant is expected to become EBITDA positive in the coming couple of quarters, with the overall drag normalizing over the next few quarters.
- Hydrogenation contrast: The brownfield hydrogenation plant at Baroda, well-integrated with existing operations, is already EBITDA positive with much higher utilization and extremely positive customer response.
Chinese Competition & Pricing Pressure
- The tariff diversion effect: Chinese producers expanded capacity substantially through 2024 and, facing US anti-dumping duties and geopolitical barriers, are redirecting volumes to non-tariff markets: India, Southeast Asia, and the EU.
- A buyer's market: The entire aroma ingredients side is a buyer's market globally, with aggressive Chinese pricing compressing selling prices across the portfolio. Management stopped short of calling it dumping but acknowledged the intensity.
- Demand-supply path to easing: As FMCG-driven fragrance consumption grows and existing capacities get absorbed, the demand-supply balance should ease gradually. No timeline was committed.
- Anti-dumping posture: The company is not currently pursuing any government tariff action but will evaluate the situation and take necessary steps if needed.
Parag Satoskar: "I would not say dumping, but they are very effectively selling those materials in the non-tariff markets like Southeast Asia, India, which is a large consumer of aroma ingredients and EU."
Camphor: A Structural Oversupply
- Domestic capacity glut: Multiple Indian players have built substantial synthetic camphor capacity, but the camphor market has not expanded to the same level, creating a classic oversupply situation with relatively less demand.
- Natural vs synthetic dynamics: Camphor imported from China is natural camphor, while Indian manufacturers produce synthetic camphor; natural camphor is difficult to use in the puja space without processing, offering some product-segment insulation.
- Bareilly performance: Despite the oversupply, the Bareilly Camphor and Terpene Chemicals division maintained strong performance, supported by festive demand and adequate feedstock supply, contributing positively to both revenue and profitability.
- Disclosure boundary: Management declined to break out retail vs camphor powder revenue within the division, sticking to its policy of reporting only the three primary divisions.
Demand Visibility & Growth Drivers
- Record volumes: Production grew 26% sequentially and 10% YoY; sales volume rose 30% QoQ and 21% YoY, driven by growth across every business division.
- Fragrance division standout: The Ambernath fragrance division delivered an outstanding quarter on festive demand, GST 2.0 tailwinds, a focus on premiumization and performance fragrances, and market-share gains with key international and national customers.
- Forward pipeline: The company is already active in RFQ cycles for H1 2026 volumes, which are looking strong even though pricing stays tight. Demand visibility across all areas of operations remains encouraging.
- Aroma ingredients volumes: Vadodara and Mahad volumes grew strongly, driven by increased output from the hydrogenation plant and the ramping up of the Mahad facility.
Balance Sheet & Cash Flow
- Inventory build is strategic, not distressed: Cash flow challenges stem from deliberate inventory decisions: camphor forward-integration stock, trading stock, and fragrance raw materials bought at what management believes are cyclical lows.
- Receivables are seasonal: The increase in receivables is tied to last-period sales and is not a collection-quality problem.
- B2C disclosure deferred: Management took internally the suggestion to include more detail on the FMCG strategy (3pine, Saraswati brands, new launches, e-commerce listings) in future presentations but provided no specifics on the call.
Parag Satoskar: "We also have taken some strategic decisions on the fragrance raw materials where we feel that the prices are at their lowest and would only go up from here."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Mahad EBITDA breakeven | Plant to become EBITDA positive | Coming couple of quarters |
| Mahad margin drag normalization | 1.5–2% point drag to fade | Next few quarters |
| Group margin restoration | Return to target range of 8–10% | Unspecified; linked to Mahad stabilization and CPR benefits |
| CPR cost-reduction benefits | Process and batch-time improvements to lift margins even at current prices | Coming quarters |
| Anti-dumping action | Evaluate situation; take necessary steps if need arises | No timeline; currently not pursuing |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Operating revenue | ₹271 cr, +15% YoY |
| Operating revenue growth QoQ | 20% over Q1 FY26 |
| EBITDA | ₹17 cr, vs ₹29 cr in Q2 FY25 |
| EBITDA margin | 6.34%, vs 8% in Q1 FY26 |
| Net profit | ₹0.74 cr, vs ₹14.78 cr in Q2 FY25 |
| PAT margin | 0.26% |
| H1 FY26 operating revenue | ₹497 cr, +10% YoY |
| H1 FY26 EBITDA | ₹35 cr, vs ₹51 cr in H1 FY25 |
| H1 FY26 EBITDA margin | 7.11%, vs 11.20% in H1 FY25 |
| H1 FY26 net profit | ₹1.24 cr, vs ₹25.75 cr in H1 FY25 |
| Net debt-to-equity | 0.60x as of 30 Sep 2025 |
| Production growth | +26% QoQ and +10% YoY |
| Sales volume growth | +30% QoQ and +21% YoY |
| Mahad plant capacity utilization | ~20–21% in the last one to two quarters, phase 1 capacity 250 MT annually |
| Baroda facility utilization (ex-hydrogenation) | 90–95% |
| Hydrogenation plant utilization (Baroda) | 65–70% |
| Bareilly plant utilization | 85–90% |
| Ambernath fragrance division utilization | 100% in one shift, expandable to 3x |
| Mahad plant EBITDA drag | 1.5% to 2% point drag on Group EBITDA |
| Implied selling price reduction | ~6% (per an analyst's math, management confirmed broadly right) |